Lumida
/PTGX
⌘K
Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

PTGX
$140.91USD↑+6.73%+8.89 today

MARKET CAP

9.1B

P/E (TTM)

—

FWD P/E

75.6x

DAY RANGE

$131 – $141

52W RANGE

$50
$141

AI Summary

Stalk
StalkMedium

PTGX remains in a Stage 2 advancing uptrend confirmed by a recent Momentum Breakout, but the stock is extended and extremely overbought. A speculative approach favors waiting for a shallow pullback into the rising 9/21 EMA support zone before engaging. Stalk for a clearer entry on structural support while monitoring for distribution risk.

  • ↑Institutional ownership ~98.6%, reflecting high hedge fund backing.
  • ↑Q1 revenue $56.4 M, above estimates, and collaboration revenue rising.
  • ↓Net loss $114.7 M and negative profitability factors persist.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a leading biotechnology company focused on developing novel drug therapies for blood disorders and inflammatory diseases. Its proprietary peptide technology platform supports the advancement of multiple clinical candidates, notably targeting conditions such as polycythemia vera (PV) and hereditary hemochromatosis (HH). With recent momentum driven by positive clinical data and strategic partnerships, Protagonist is well-positioned to capitalize on unmet medical needs in the healthcare sector.

Bull says

  • ↑Institutional ownership ~98.6%, reflecting high hedge fund backing.
  • ↑Q1 revenue $56.4 M, above estimates, and collaboration revenue rising.
  • ↑Stock price +144% past year; +22% last month indicates momentum.
  • ↑Milestones: PDUFA for rusfertide in Aug 2026, Phase III Icotrokinra H2 2026.
  • ↑Analysts expect profitability in 2024 after strong pipeline progress.
  • ↑High growth and momentum factors support further upside potential.

Bear says

  • ↓Net loss $114.7 M and negative profitability factors persist.
  • ↓Regulatory pathway remains uncertain, risking trial delays and approvals.
  • ↓Leverage risk elevated as funding clinical trials strains cash.
  • ↓Share price may be overvalued given negative earnings yield.
  • ↓Competes with established IBD therapies, casting doubt on PN943 uptake.
  • ↓Negative rate sensitivity and small market size factors add macro risk.

Investment themes with PTGX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2020 · Mgmt. Guidance

Updated 07-02-2026neutral

Transcript signals

Bull points

  • five different new chemical entities, or NCEs, that are being advanced in six different clinical studies, and all of these studies are expected to be completed over the next two years.
  • Respartide appears to be safe, well-tolerated, and very effective in managing hematocrit control, below 45% across the 18 adult patients evaluated.
  • This analysis further confirms our belief that there is a large and glaring need for better treatment options for these PV patients.

Bear points

  • Well, the unknowns are the unknowns, and I think, you know, we sound like a broken record, but I think it's still the most meaningful statement.
  • The second part, which is randomized and blinded, that would require the last person completing the study before we could update that part of the study.
  • we reported a net loss of $18.9 million or a net loss of $0.48 per share compared to a net loss of $17.5 million or a net loss of $0.63 per share for the fourth quarter of 2019.
Read full transcript analysis ›